Lv53
860 积分 2022-12-05 加入
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
1小时前
已完结
Senescence as a therapeutic target in cancer and age-related diseases
1小时前
已完结
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
2小时前
已完结
Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent
8小时前
已完结
Discovery and Total Synthesis of Anhydrotuberosin as a STING Antagonist for Treating Autoimmune Diseases
8小时前
已完结
A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study
1天前
已关闭
147 (PB135): Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated pharmacological properties in xenograft tumor models
1天前
已完结
Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile
2天前
已完结
Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile
2天前
已关闭
Proline Analogues in Drug Design: Current Trends and Future Prospects
6天前
已完结
皖公网安备34019202002308
